An uncharted country

Clinical Oncology

Volumn 11, Issue 2, 1999, Pages 71-72

  Macbeth, F ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; COST OF ILLNESS; EDITORIAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0033031294     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.1999.9016     Document Type: Editorial

References (8)

1. M Saunders S Dische A Barrett Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer Lancet 350 1997 161 165
2. AJ Bailey M KB Parmar RJ Stephens Patient-reported short term and long term physical and psychologic symptoms: results of the continuous hyperfractionated radiotherapy (CHART) randomized trial in non-small cell lung cancer J Clin Oncol 16 1998 3082 3093
3. .Scottish Intercollegiate Guidelines Network. Management of lung cancer. A national clinical guideline recommended for use in Scotland. Edinburgh: SIGN,1998.
4. Clin Oncol 11 1999 S1 S54
5. Guidance on commissioning cancer services: improving outcomes in lung cancer 1998 NHS Executive Leeds:
6. D Coyle MF Drummond on behalf of the Medical Research Council CHART Steering Committee. Cost of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus Clin Oncol 9 1997 313 321
7. JD Cox N Azarnia RW Byhardt A randomized Phase I/II trial of hyperfractionated radiation therapy with total doses of 60.9 to 79.2 Gy: possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small cell lung carcinoma: report of the RTOG 83–11 J Clin Oncol 8 1990 1543 1555
8. BMJ 311 1995 899 909